Intradermal blue dye to identify sentinel lymphnode in breast cancer [3]

Lancet

Volumn 349, Issue 9066, 1997, Pages 1668-1669

  Borgstein, P J ^a   Meijer, S ^a   Pijpers, R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISULFINE BLUE;

ADULT; AXILLARY LYMPH NODE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTRADERMAL DRUG ADMINISTRATION; LETTER; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM; PRIORITY JOURNAL; SCINTISCANNING; STAINING;

EID: 0030999632     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62634-7     Document Type: Article

References (5)

1. Cady B. The need to reexamine axillary lymph node dissection in invasive breast cancer. Cancer 1994; 73: 505-08.
2. Giuliano AE, Kirgan DM, Geunther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220: 391-401.
3. Pijpers R, Meijer S, Hoekstra OS, et al. Impact of lymphoscintigraphy on sentinel node identification with Technetium-99m colloidal albumin in breast cancer. J Nucl Med 1997; 38: 366-68.
4. Grant RN, Tabah EJ, Adair FE. The surgical significance of the subareolar plexus in cancer of the breast. Surgery 1959; 33: 71-78.
5. Turner-Warwick RT. The lymphatics of the breast. Br J Surg 1953; 46: 574-82.